New Year Bumper Sale @ Rs. 1 X
Blumika 250 Mg Injection, a prescription drug, is manufactured in various forms such as Injection. It is primarily used for the treatment of Urinary Tract Infection. Other than this, Blumika 250 Mg Injection has some other therapeutic uses, which have been discussed ahead.
The right dosage of Blumika 250 Mg Injection depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
Some other side effects of Blumika 250 Mg Injection have been listed ahead. These side effects of Blumika 250 Mg Injection are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Blumika 250 Mg Injection's effect during pregnancy is Severe and Unknown while nursing. Further, the section on Blumika 250 Mg Injection related warnings talks about Blumika 250 Mg Injection's effects on the liver, heart and kidney.
Blumika 250 Mg Injection is contraindicated in people with pre-existing medical conditions like Dehydration, Parkinson's Disease, Hearing Loss as it can result in adverse effects. The section on Blumika 250 Mg Injection contraindications lists all such conditions.
Besides this, Blumika 250 Mg Injection may also have severe interaction with some medicines. See below for a complete list.
You should also be aware that Blumika 250 Mg Injection is safe while driving, and is addiction.
Blumika 250 Mg Injection is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
2 - 12 years (Child) |
|
Is the use of Blumika 250 Mg Injection safe for pregnant women?
Blumika shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Blumika 250 Mg Injection safe during breastfeeding?
Due to lack of research work on this topic, the side effects of Blumika for breastfeeding women are not known.
What is the effect of Blumika 250 Mg Injection on the Kidneys?
Blumika may have severe effects on your kidney, so do not take it without consulting your doctor.
What is the effect of Blumika 250 Mg Injection on the Liver?
Very few cases of side effects of Blumika on the liver have been reported.
What is the effect of Blumika 250 Mg Injection on the Heart?
Very few cases of side effects of Blumika on the heart have been reported.
Blumika 250 Mg Injection should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
If you are suffering from any of the following diseases, you should not take Blumika 250 Mg Injection unless your doctor advises you to do so -
Is this Blumika 250 Mg Injection habit forming or addictive?
Blumika 250 Mg Injection is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Blumika 250 Mg Injection since it does not cause drowsiness.
Is it safe?
Yes, but consume Blumika 250 Mg Injection only on doctor's advice.
Is it able to treat mental disorders?
No, Blumika 250 Mg Injection cannot treat any kind of mental disorder.
Interaction between Food and Blumika 250 Mg Injection
Taking Blumika 250 Mg Injection with food is safe.
Interaction between Alcohol and Blumika 250 Mg Injection
Due to lack of research, there is no information about the side effects of taking Blumika 250 Mg Injection with alcohol.
No, Blumika does not cause constipation in patients who are taking it. However, if you are experiencing constipation after taking this drug then inform your doctor and take precautionary methods such as eating fibrous foods to avoid constipation.
Do not self-administer Blumika. It comes in the form of injection and given preferably 2 - 3 times in a day (Intravenously). Discontinuing the medicine in between may promote resistant bacteria which result in a relapse of the infection. You are recommended to complete the 7 - 10 days course even after getting symptomatic relief. In case you feel any discomfort such as hearing loss and nephrotoxicity while taking Blumika please inform your doctor immediately.
Yes, Blumika is effective against bacteria (Pseudomonas). But it is also found that Pseudomonas can get resistant to this drug and in that case Blumika will not produce desired results. If you are experiencing no symptomatic relief after taking this medicine then inform your doctor and follow his/her instructions.
Blumika is a brand name for amikacin. It is a prescription drug which belongs to the class of medication known as an aminoglycoside antibiotic. It is a broad spectrum antibiotic which is used for the treatment of bacterial infection such as bone, joint, skin, intra-abdominal, pneumonia, and respiratory tract infection. It is used for short-term treatment (7 - 10 days) of bacterial infection in different part of the body. It is also used for the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.
Blumika is a broad-spectrum antibiotic which is active against both Gram-positive and Gram-negative bacteria. It works by preventing the synthesis of proteins that bacteria need to survive, in the absence of protein synthesis bacteria become vulnerable and dies. It is effective against different types of bacteria such as Escherichia coli, Proteus species, S. aureus, Acinetobacter and Serratia species.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Arikayce (amikacin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 749
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 136-137